Management, along with KOL Dr. Jamy, principal investigator of the Phase 3 REGAL study at the University of Alabama at Birmingham, discuss Galinpepimut-S a potential treatment for Acute Myeloid Leukemia on a conference call to be held on January 31 at 8:30 am. Webcast Link
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SLS:
- Sellas Life Sciences to hold a conference call
- Sellas Life Sciences to host KOL webinar on GPS AML program
- SELLAS Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia Program
- Sellas Life Sciences appoints Elnatan as VP, Head of Regulatory Affairs, CMC
- SELLAS Life Sciences Strengthens Leadership Team with Appointment of Vice President Head of Regulatory Affairs
